Amerpharma
Amerpharma, officially known as Amerpharma Sp. z o.o., is a prominent player in the pharmaceutical industry, headquartered in Poland. Established in 2005, the company has rapidly expanded its operations across Europe, focusing on the development and distribution of high-quality pharmaceutical products. Specialising in generic medicines, Amerpharma is recognised for its commitment to innovation and quality, offering a diverse portfolio that includes both prescription and over-the-counter medications. The company’s unique approach to research and development has positioned it as a trusted partner in the healthcare sector, contributing to improved patient outcomes. With a strong market presence and a reputation for excellence, Amerpharma continues to achieve significant milestones, reinforcing its status as a leader in the pharmaceutical landscape.
DitchCarbon Score
How does Amerpharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amerpharma's score of 0 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Amerpharma's reported carbon emissions
Amerpharma, headquartered in Poland, currently does not have available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This lack of data suggests that Amerpharma may still be in the early stages of formalising its climate commitments or reporting its emissions. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and reducing their carbon footprints, often setting ambitious targets aligned with global climate goals. As Amerpharma moves forward, establishing clear emissions data and reduction strategies will be essential for enhancing its environmental impact and meeting industry standards.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amerpharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
